Alexandre Hohl
Overview
Explore the profile of Alexandre Hohl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
425
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmidt P, Pasqualotto E, Dos Santos H, de Souza L, Dos Santos B, Chavez M, et al.
Obes Res Clin Pract
. 2025 Feb;
19(1):11-18.
PMID: 39904668
Aim: To evaluate the effect of liraglutide on body composition in people living with obesity or overweight. Methods: A systematic search was conducted in PubMed, Embase, and Cochrane Library databases...
2.
Moreira R, Valerio C, Hohl A, Moulin C, Moura F, Trujilho F, et al.
Arch Endocrinol Metab
. 2024 Dec;
68():e240422.
PMID: 39664998
Pharmacological treatment of obesity is passing through many changes in the last decades; different agents have been approved, and newer options are leaning towards higher efficacy and a more favourable...
3.
Lutkemeyer C, Pasqualotto E, Ferreira R, Chavez M, Petris Jr I, Dos Santos H, et al.
Arch Endocrinol Metab
. 2024 Oct;
68:e230469.
PMID: 39420937
The aim of this study is to assess the effects of once-daily oral orforglipron on weight and metabolic markers in adult patients. PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were...
4.
Pasqualotto E, Ferreira R, Chavez M, Hohl A, Ronsoni M, Pasqualotto T, et al.
Metabol Open
. 2024 Sep;
24:100321.
PMID: 39318607
Aim: To assess the effects of once-weekly subcutaneous retatrutide on weight and metabolic markers and the occurrence of side effects in patients with overweight, obesity and/or type 2 diabetes (T2D)....
5.
Chavez M, Pasqualotto E, Ferreira R, Hohl A, de Moraes F, Schmidt P, et al.
Climacteric
. 2024 Jul;
27(4):436-437.
PMID: 38973476
No abstract available.
6.
Chavez M, Pasqualotto E, Ferreira R, Hohl A, de Moraes F, Schmidt P, et al.
Climacteric
. 2024 Apr;
27(3):245-254.
PMID: 38619017
This systematic review and meta-analysis investigated the efficacy and safety of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. PubMed, Cochrane Library, Embase and Web of...
7.
Rigon F, Ronsoni M, Hohl A, Daher Vianna A, van de Sande-Lee S, Schiavon L
J Diabetes Sci Technol
. 2024 Mar;
:19322968241232686.
PMID: 38439562
Aim: To evaluate the use of intermittently scanned continuous glucose monitoring (isCGM) in patients with liver cirrhosis (LC). Methods: Observational study including 30 outpatients with LC (Child-Pugh B/C): 10 without...
8.
Bertoluci M, Silva Junior W, Valente F, Araujo L, Lyra R, Jacome de Castro J, et al.
Diabetol Metab Syndr
. 2023 Jul;
15(1):160.
PMID: 37468901
Background: The management of antidiabetic therapy in people with type 2 diabetes (T2D) has evolved beyond glycemic control. In this context, Brazil and Portugal defined a joint panel of four...
9.
Rigon F, Ronsoni M, Daher Vianna A, Schiavon L, Hohl A, van de Sande-Lee S
Arch Endocrinol Metab
. 2022 Jun;
66(6):883-894.
PMID: 35657123
The management of diabetes mellitus (DM) requires maintaining glycemic control, and patients must keep their blood glucose levels close to the normal range to reduce the risk of microvascular complications...
10.
Sposito A, Bonilha I, Luchiari B, Benchimol A, Hohl A, Moura F, et al.
Obes Rev
. 2021 Apr;
22(6):e13224.
PMID: 33847068
Despite being approved for clinical use, evidence of cardiovascular safety (CV) is lacking for treatment with bupropion, naltrexone, or their combination (B-N). The purpose of the study is to determine...